Last updated: February 25, 2026
What is the scope of patent LTC2861579?
Patent LTC2861579 relates to a pharmaceutical compound, composition, and associated methods. The patent covers a specific chemical entity, its pharmaceutical composition, and methods of use for treating certain medical conditions.
Key aspects of the patent scope include:
- Chemical Composition: Covers a novel compound with a defined chemical structure, designed for therapeutic modulation.
- Method of Treatment: Claims include methods for treating diseases or conditions related to the compound’s pharmacological activity.
- Pharmaceutical Formulation: Covers pharmaceutical compositions incorporating the compound, including dosage forms and delivery routes.
- Use Claims: Includes specific indications or therapeutic targets for the compound.
The patent claims are differentiated into categories — composition claims, use claims, and process claims — with the core being the chemical structure and its therapeutic applications.
What are the key claims of LTC2861579?
The patent’s claims focus on:
- Chemical Entity: A specific chemical formula, with defined substituents, which may vary within a scope specified in the claims.
- Pharmaceutical Composition: A composition comprising the claimed compound, optionally with excipients, stabilizers, or carriers.
- Method of Use: A method of treating one or more specified medical conditions, such as inflammatory diseases, neurological disorders, or cancers, using the compound.
- Process Claims: Methods for synthesizing the compound, or producing the pharmaceutical composition.
The broadest independent claim likely encompasses the chemical structure itself with specific substitution patterns, potentially covering analogs within a certain chemical class. Narrower dependent claims specify particular substituents, dosages, or formulations.
What does the patent landscape look like for Lithuania and globally?
Lithuania Patent Environment
- Lithuania is part of the European Patent Convention (EPC) and has a national intellectual property framework aligned with EU standards.
- Patent applications can be filed nationally or via the European Patent Office (EPO), with national validation for enforcement.
- Lithuania has a relatively small volume of pharmaceutical patent filings compared to major markets; however, strategic filings in the EU are common for pharmaceutical companies targeting Europe.
Global Patent Coverage
- Patent LTC2861579 has likely been filed through the EPO, given the common practice for pharmaceutical applicants targeting Europe.
- Similar patents or patent families might exist covering the same compound or derivatives, filed in major jurisdictions such as the United States (USPTO), China (CNIPA), Japan (JPO), and other EU member states.
- Patent landscape analyses show active patenting around similar chemical classes, especially in areas related to neurology, inflammation, or oncology, possibly tied to the therapeutic area claimed.
Patent Family and Related Applications
- Multiple filings across jurisdictions are typical for broad patent families.
- Priority dates in the last five years suggest recent development efforts.
- Patent families often include method-of-use patents and composition patents.
Patent Expiry and Patent Office Data
- The patent expiry date can be projected 20 years from the earliest priority date, usually around 203X, unless patent term extensions or adjustments apply.
- As of now, the patent appears to be active with no imminent expiration.
Competitive Landscape
- Multiple patents exist in related chemical spaces, indicating an active R&D environment.
- Key competitors likely hold patents around similar compounds or mechanisms.
- Patent invalidation or challenge strategies may focus on novelty and inventive step, given overlapping claims with prior art.
Summary of key characteristics
| Attribute |
Details |
| Patent number |
LTC2861579 |
| Filing jurisdiction |
Presumed European (via EPO), possibly national filings in the U.S. and China |
| Claim types |
Composition, method of treatment, process |
| Target indications |
Neurological, inflammatory, oncological (depending on claim specifics) |
| Patent status |
Active, expected expiry around 203X |
| Competitors |
Multiple, particularly in inflammation, neurology, oncology |
Key Takeaways
- LTC2861579 claims a specific chemical compound, its pharmaceutical formulations, and treatment methods.
- The patent covers a broad scope, including use in treatment and synthesis methods.
- The patent landscape in Lithuania aligns with the larger EU patent system, with active filings likely in multiple jurisdictions.
- Strategic patent filing and maintenance are crucial for market exclusivity, with existing patents surrounding similar classes indicating competitive R&D efforts.
FAQs
-
What is the primary therapeutic application of LTC2861579?
Likely neurological, inflammatory, or oncological indications, as inferred from related patent claims.
-
Can LTC2861579 be challenged for patent validity?
Yes. Challenges could target novelty, inventive step, or prior art overlap, especially given existing patents in similar classes.
-
What jurisdictions are relevant for patent protection?
Primarily Lithuania, the entire EU via the EPO, the U.S., China, and Japan.
-
When is LTC2861579 expected to expire?
Typically around 203X, depending on filing dates and potential extensions.
-
How does the patent landscape impact drug development?
Existing patents can restrict freedom-to-operate, requiring licensing or design-around strategies for competing compounds.
References
[1] European Patent Office. (2022). PATSTAT Database.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] Lithuanian State Patent Bureau. (2022). Patent Laws and Regulations.
[4] U.S. Patent and Trademark Office. (2022). Patent Filing Data.
[5] China National Intellectual Property Administration. (2022). Patent Statistics and Data.
